A Maine woman who says her sick cat kept failing to improve on thyroid medication has filed a proposed class action against Wedgewood Pharmacy, the Gloucester County compounding giant now in the middle of a sprawling nationwide drug recall. The suit, filed in the name of Nancy Wolach, demands more than $5 million and seeks to represent consumers who bought any of the medications now being pulled from the market.
Wolach filed a proposed class action against Wedgewood, according to Courier-Post. Wedgewood is described in the filing as the nation's largest veterinary compounding pharmacy, operating out of Logan Township in Gloucester County, New Jersey.
At the heart of the complaint is Wolach's cat.
A Recall Covering Nearly 4,000 Product Listings
The lawsuit lands weeks after Wedgewood announced a voluntary recall on Oct. 21 covering nearly 4,000 compounded veterinary product listings. As dvm360 reported, that figure refers to individual product listings rather than the total number of affected lots, and the recalled items were shipped to veterinary practices, pharmacies, and other customers across the country between Feb. 18 and Oct. 6, 2026.
Wedgewood has said the recall stemmed from internal quality concerns rather than confirmed harm. In its own recall notice, the company said it identified inconsistencies in certain analytical testing data that affected its confidence in that testing data, and it added that it had not identified an increase in reported complaints or adverse events tied to the affected products.
Figures cited by the American Veterinary Medical Association paint a more specific picture of the complaint volume. According to the American Veterinary Medical Association, Wedgewood had received 98 complaints associated with the recalled products as of Oct. 21, seven of which were described as serious; the company's chief veterinary officer said that figure represented roughly 0.04% of prescriptions filled for the recalled products.
What Wedgewood Is Telling Customers
The AVMA says veterinary practices and pharmacies should examine inventory and quarantine affected products.
Wolach's case is a proposed class action. The suit seeks to represent any consumer who purchased medications swept up in Wedgewood's recall, though the full scope of that potential class, and how the litigation will proceed, remains to be seen.
